Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) EBITDA (2016 - 2025)

Cytokinetics (CYTK) has disclosed EBITDA for 16 consecutive years, with -$352.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA changed N/A to -$352.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$812.8 million, a N/A change, with the full-year FY2025 number at -$786.7 million, down 34.0% from a year prior.
  • EBITDA was -$352.6 million for Q4 2025 at Cytokinetics, down from -$162.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$20.7 million in Q2 2022 to a low of -$352.6 million in Q4 2025.
  • A 5-year average of -$122.3 million and a median of -$129.3 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 2042.07% in 2021, then soared 66.37% in 2022.
  • Cytokinetics' EBITDA stood at -$31.4 million in 2021, then crashed by 331.6% to -$135.4 million in 2022, then dropped by 0.46% to -$136.0 million in 2023, then fell by 13.31% to -$154.1 million in 2024, then crashed by 128.77% to -$352.6 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's EBITDA are -$352.6 million (Q4 2025), -$162.2 million (Q1 2025), and -$154.1 million (Q3 2024).